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Introduction {#sec1}
============

Pluripotent stem cells (PSCs) can self-renew indefinitely and harbor the capability to generate almost all cells of an organism, thus holding a great promise in medical applications ([@bib10], [@bib41]). Mouse embryonic stem cells (ESCs), the first derived PSCs, were obtained from the inner cell mass of the blastocyst ([@bib13], [@bib42]). Epiblast stem cells (EpiSCs), a newer type of PSCs, were derived from the post-implantation embryo of the mouse ([@bib6], [@bib54]). It was proposed that ESCs and EpiSCs represent two different states of pluripotency: the naive and primed state, corresponding to pre- and post-implantation epiblasts *in vivo*, respectively ([@bib40]). ESCs cultured in conventional serum/feeder systems are heterogonous cells with multiple pluripotent states. By contrast, ESCs cultured in 2i/LIF, i.e., ground-state ESCs or naive ESCs (nESCs), are relatively homogeneous. The nESCs harbor unique characteristics including high capability of colony formation, expression of naive pluripotency genes, global DNA hypomethylation, reactivation of two X chromosomes in female cells, and uses of both glycolysis and oxidative metabolism, mostly reflecting naive pluripotency *in vivo* ([@bib20]). Furthermore, nESCs can be converted into epiblast-like cells (EpiLCs) *in vitro* ([@bib21]), representing an intermediate state between nESCs and EpiSCs ([@bib26], [@bib31]).

The naive-state PSCs were initially derived in rodents including mouse ([@bib33]) and rat ([@bib22]). Recently, human naive-like PSCs were generated by overexpression of naive pluripotency factors ([@bib52], [@bib55]) or by isolating directly from early embryos ([@bib17]). Human naive PSCs are similar to rodent PSCs on global transcriptional state, core transcription factor networks, and metabolism properties; however, there are still significant discrepancies regarding signaling profile and epigenetic identity ([@bib3]), suggesting that our understanding of the molecular mechanisms of the naive state remains incomplete.

Long noncoding RNAs (lncRNAs), transcripts longer than 200 nucleotides without protein-coding capability, can regulate gene expression at transcriptional and post-transcriptional levels. They are emerging as important players in many biological processes including embryonic development, stem cell self-renewal, and differentiation ([@bib15], [@bib39], [@bib45]). As one of the most commonly used cell models for lncRNA studies, PSCs have been extensively profiled for RNA expression, epigenetic modifications, and RNA-protein interactions ([@bib18], [@bib19], [@bib28]). Functional studies have indicated that lncRNAs are involved in the self-renewal of PSCs through regulating key pluripotency factors ([@bib27], [@bib44], [@bib49]), mediating chromatin modifications ([@bib9], [@bib25], [@bib35]), or sponging/counteracting microRNAs ([@bib36], [@bib57]). However, the lists of potentially functional lncRNAs in ESCs that have been reported by different studies overlap poorly ([@bib19], [@bib27]), which suggests that the functions of lncRNAs in PSCs are still not yet fully understood. Here we profiled genome-wide lncRNA expressions in mouse nESCs and their derived EpiLCs, and investigated the functions of one of the highly expressed lncRNAs in nESCs.

Results {#sec2}
=======

The Profiling of lncRNAs in Mouse nESCs and EpiLCs {#sec2.1}
--------------------------------------------------

To investigate the transcripts of nESCs and EpiLCs, we performed strand-specific, ribosomal RNA-depleted RNA sequencing (RNA-seq) experiments in two independent mouse ESC lines ([Figure 1](#fig1){ref-type="fig"}A). Through differential expression (DE) analysis between nESCs and EpiLCs, 2,227 DE genes are detected ([Figure 1](#fig1){ref-type="fig"}B), including 2,025 mRNAs (1,196 upregulated and 829 downregulated) and 202 lncRNAs (67 upregulated and 135 downregulated). The full list of DE lncRNA genes is provided in [Table S1](#mmc2){ref-type="supplementary-material"}.Figure 1Profiling of Transcripts in nESC-to-EpiLC Transition(A) Cell morphology changes during nESC-to-EpiLC transition and numbers of uniquely mapped reads from RNA-seq experiments conducted in two cell lines (E14 and R1).(B) The volcano plot showing differentially expressed genes between nESCs and EpiLCs. Fold changes (log2) are plotted on the x axis, and q values (−log10 scale) are plotted on the y axis. Significantly changed genes (q \< 0.05, log2 fold changes \>2 or \<−2) are indicated in blue (mRNAs) and orange (lncRNAs). Purple dots denote representative genes. See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.(C) Chromatin features in the *Lncenc1* locus. The top track shows normalized reads densities of RNA-seq results of nESCs. Tracks below show signals of histone modifications, TF binding, and the super-enhancer domain. P300, Oct4, H3K27ac, and H3K4me1 ChIP-seq data were from GEO: [GSE56138](ncbi-geo:GSE56138){#intref0025}; H3K4me3, H3K27me3, H3K36me3, and H3K9me3 ChIP-seq data were from GEO: [GSE23943](ncbi-geo:GSE23943){#intref0030}. Coordinates of super-enhancer domains were obtained from [@bib12]. The lncRNA named *lincenc1* ([@bib47]) is shown in red at the bottom track.

To examine the functions of lncRNAs preferentially expressed in nESCs, we tested seven lncRNAs in the lists through small hairpin RNA (shRNA)-based RNAi. We selected these lncRNAs because they are relatively enriched in nESCs, and their functions remain unknown. We achieved a significant depletion of greater than 40% with both shRNAs targeting four of seven lncRNAs tested (*Lncenc1*, *Panct2*, *GM13110*, and *GM805*). Depletion of each of these lncRNAs was associated with a significant reduction in Oct4 and/or Nanog mRNA levels, along with visible flatting of clone morphologies, suggesting that these lncRNAs may play roles in maintaining the state of nESCs ([Figure S1](#mmc1){ref-type="supplementary-material"}).

*Lncenc1* Is Specifically Expressed in nESCs and Is Highly Dynamic during Differentiation {#sec2.2}
-----------------------------------------------------------------------------------------

Among these lncRNAs, we decided to focus on *Lncenc1*, as (1) it is the most abundant lncRNA that is differentially expressed in nESCs ([Table S1](#mmc2){ref-type="supplementary-material"}); (2) its gene locus overlaps a super-enhancer domain ([Figure 1](#fig1){ref-type="fig"}C), suggesting that it is potentially functional; and (3) it is specifically expressed in nESCs relative to somatic tissues ([Figure 2](#fig2){ref-type="fig"}A). We noticed a published mouse work, which knocked out a lncRNA named as *lincenc1* ([@bib47]), but the reported sequence transcribes from the opposite direction and does not overlap with the *lncenc1* gene we studied here ([Figure 1](#fig1){ref-type="fig"}C).Figure 2Characterization of *Lncenc1* and Its Expression Dynamics during ESC Differentiation(A) Expression of *Lncenc1* in mouse nESCs and somatic tissues as measured by qRT-PCR. Expression levels were normalized against *Actb*. Results are shown as means ± SD of three independent experiments.(B) The *Lncenc1* transcript detected by northern blot analysis. The agarose gel imaging (black background) underneath the blot (gray background) shows total RNA used for analysis.(C) RNA *in situ* hybridization (RNAscope) targeting *Lncenc1* in mouse nESCs and EpiLCs. *Ppib* was used as a positive control. Nuclei were stained with DAPI. Scale bars, 5 μm.(D) Relative expression levels of *Lncenc1* in cytoplasm, nucleoplasm, or chromatin fractions as determined by qRT-PCR analysis of RNA extracted from each fraction. *Neat1* and *Actb* were used as controls. Data are the means ± SD of three independent experiments. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(E and F) Expression dynamics of two pluripotency genes (*Oct4* and *Nanog*) and *Lncenc1* during the nESC-to-EpiLC transition (E), and during spontaneous differentiation (F). Expression levels were normalized against *Actb*. Results are shown as means ± SD of three independent experiments. Data are compared with 0 hr. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.See also [Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C.

To test the completeness of the *Lncenc1* transcript, we performed northern blot analysis. The data showed that the transcript is about 3,400 nucleotides in size in nESCs, but was almost undetectable in EpiLCs ([Figure 2](#fig2){ref-type="fig"}B). According to our RNA-seq data ([Figure 1](#fig1){ref-type="fig"}C) and RT-PCR analysis ([Figure S2](#mmc1){ref-type="supplementary-material"}A), the shorter isoform (NR_110430) expresses in nESCs rather than the longer one (NR_110432). Furthermore, both RNA FISH and cellular fraction experiments indicated that transcripts of *Lncenc1* located in both the nucleus and cytoplasm of mouse nESCs ([Figures 2](#fig2){ref-type="fig"}C and 2D).

To study dynamic changes of *Lncenc1* expression during the nESC-to-EpiLC transition, we measured its expression over a 72-hr time window in E14 nESCs. The results showed that the expression level is relatively stable during the first 24 hr, but then decreases dramatically and becomes nearly undetectable after 72 hr ([Figure 2](#fig2){ref-type="fig"}E). Similar dynamics were observed in spontaneous differentiation induced by the withdrawal of 2i/LIF from the medium, and the decline of *Lncenc1* expression happened earlier at around hour 6 ([Figure 2](#fig2){ref-type="fig"}F). Interestingly, the decline of *Lncenc1* expression occurred after *Nanog* but before *Oct4* in both cases; this suggests that *Lncenc1* could be involved in pluripotency networks, consistent with a recent observation that the expression profile of *Lncenc1* is associated with known pluripotency genes ([@bib4]). Similar expression dynamics were also observed in the R1 cell line ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C), indicating a general role of *Lncenc1* in nESCs. Functional experiments thereafter were performed only in E14 cells unless otherwise stated.

Lncenc1 Is Required for Self-Renewal in nESCs {#sec2.3}
---------------------------------------------

To investigate the function of *Lncenc1*, we knocked down its expression in nESCs by two independent shRNAs, which can deplete 70%--80% of *Lncenc1* transcripts as shown by qRT-PCR. As a result, the expression of six pluripotency genes decreases significantly, although the magnitude of deduction is usually less than 50% ([Figure 3](#fig3){ref-type="fig"}A). Consistently, protein levels of OCT4, NANOG, and SOX2 are decreased in *Lncenc1* knockdown cells as shown by western blot and immunofluorescence ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Moreover, clone morphologies changed from "round and tight" to "flat and loose," and alkaline phosphatase staining became weaker in *Lncenc1*-knockdown cells ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}C). As *Lncenc1* transcripts locate in both nucleus and cytosol, we also conducted antisense oligonucleotide (ASO)-mediated gene silencing, which showed higher knockdown efficiency compared with RNAi for nuclear RNAs ([@bib32]). Consistently, when *Lncenc1* was suppressed by two independent ASOs, expression levels of core pluripotency genes were significantly decreased ([Figure S3](#mmc1){ref-type="supplementary-material"}D).Figure 3*Lncenc1* Is Required to Maintain the Self-Renewal of Mouse nESCs(A) Expression levels of six pluripotency genes as measured by qRT-PCR in nESCs upon shRNA-mediated knockdown of *Lncenc1*. Expression levels were normalized against *Actb*. Results are shown as means ± SD of three independent experiments. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(B) Bright-field micrographs (upper panels) and alkaline phosphatase staining in control nESCs and *Lncenc1* knockdown ESCs. Scale bars, 200 μm. See also [Figure S3](#mmc1){ref-type="supplementary-material"}C.(C) Expression of pluripotency genes in wild-type (Ctrl.) and *Lncenc1* KO nESCs. Upper panel: the schematic representation of CRISPR/Cas9-mediated knockouts of the *Lncenc1* locus. Four KO clones were obtained by depletion of the whole gene (KO1 and KO2) or depletion of the largest exon (KO3 and KO4). Expression levels were normalized against *Actb*. Results are shown as means ± SD of three independent experiments. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(D) Results of colony formation experiments in control and *Lncenc1* knockdown or KO nESCs. Clone numbers are shown as means ± SD of three replicates. Statistical significance of t test: ^∗∗^p \< 0.01.(E) Bright-field micrographs of control nESCs and *Lncenc1*-overexpressed ESCs in 2I/LIF (left) and then withdrawal of 2i/LIF for 2 days (right). Scale bars, 200 μm.(F) Expression levels of pluripotency genes of control nESCs and *Lncenc1*-overexpressed ESCs in 2i/LIF (0d) and spontaneous differentiation (1d, 2d). Expression levels were normalized against *Actb*. Results are shown as means ± SD of three independent experiments. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

To further rule out potential off-target effects of shRNA- or ASO-based gene silencing, we generated *Lncenc1* knockout (KO) cell lines through CRISPR/Cas9-based genome editing technology. We successfully established four KO cell lines by deleting the entire gene locus or the largest exon, and *Lncenc1* transcripts were almost completely depleted in these cells. Compared with wild-type cells, the expression of pluripotency genes is significantly reduced in all these KO cell lines ([Figure 3](#fig3){ref-type="fig"}C). More important, colony formation capability, a proxy for self-renewal efficiency ([@bib41]), was significantly decreased in knockdown and KO cells ([Figure 3](#fig3){ref-type="fig"}D).

To test whether *Lncenc1* is sufficient to maintain the naive state, we overexpressed *Lncenc1* (OE) in nESCs and then withdrew 2i/LIF for 2 days. The morphology of OE cells is more "naive-like" compared with the control ([Figure 3](#fig3){ref-type="fig"}E). In the 2i/LIF culture (day 0), the expression levels of pluripotency genes tested are all significantly increased in the OE cells ([Figure 3](#fig3){ref-type="fig"}F). After the withdrawal of 2i/LIF for 1 day, the expression levels of pluripotency genes, especially naive-state genes (*Nanog*, *Tbx3*, *Rex1*, and *Esrrb*), remain significantly higher, whereas those of post-implantation genes (*Fgf5* and *Dnmt3b*) are significantly lower in the OE cells, suggesting that the overexpression of *Lncenc1* in nESCs delays their differentiation. On day 2, the expression levels of pluripotency genes decrease further and are comparable between OE and control cells. Therefore, *Lncenc1* is required but not sufficient to keep the ESCs in a naive state.

*Lncenc1* Controls the Glycolysis Pathway in nESCs {#sec2.4}
--------------------------------------------------

To reveal global gene expression changes upon *Lncenc1* depletion, we conducted RNA-seq experiments with control and knockdown cells and identified 101 downregulated and 182 upregulated genes ([Figure 4](#fig4){ref-type="fig"}A; [Table S2](#mmc3){ref-type="supplementary-material"}). Functional annotation of these affected genes indicated that they are highly enriched in the glycolysis/gluconeogenesis pathway ([Figure 4](#fig4){ref-type="fig"}B). We then examined mRNA expression with qRT-PCR in knockdown (by shRNAs and ASOs) and KO nESCs and confirmed that these glycolysis genes detected by RNA-seq are all significantly decreased upon depletion or deletion of *Lncenc1* ([Figures 4](#fig4){ref-type="fig"}C, 4D, and [S3](#mmc1){ref-type="supplementary-material"}E). Consistently, protein levels of these glycolytic enzymes are markedly decreased in *Lncenc1* knockdown and KO cells as determined by western blotting ([Figure 4](#fig4){ref-type="fig"}E). Furthermore, upon the overexpression of *Lncenc1* in nESCs, the mRNA levels of glycolysis genes are upregulated significantly; however, after spontaneous differentiation, the control and OE ESCs display similar dynamic changes on these glycolysis genes ([Figure 4](#fig4){ref-type="fig"}F).Figure 4*Lncenc1* Regulates the Glycolysis Pathway in nESCs(A) The heatmap of differentially expressed genes upon *Lncenc1* knockdown as identified by RNA-seq experiments.(B) Significantly enriched pathways (p \< 0.05) of differentially expressed genes upon *Lncenc1* knockdown as revealed by KEGG pathway analysis. Lower panel: the schematic showing of the glycolysis pathway and significantly downregulated genes (in red) upon *Lncenc1* depletion.(C and D) Expression of glycolysis genes in the *Lncenc1* knockdown or KO nESCs. (C) knockdown by shRNAs; (D) KO by CRISPR/Cas9. Data were normalized against *Actb* and are shown as means ± SD of three independent experiments. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}B.(E) Protein levels of glycolytic enzymes in *Lncenc1* knockdown (left) or KO (right) nESCs as detected by western blot analysis. ACTB and H3 were used as the loading controls.(F) Expression levels of glycolysis genes in control and *Lncenc1*-overexpressed ESCs in 2i/LIF (0d) and spontaneous differentiation (1d, 2d). Data were normalized against *Actb* and are shown as means ± SD of three independent experiments. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

To test whether the functions of *Lncenc1* can be rescued in its depleted or deleted cells, we have re-expressed *Lncenc1* in the knockout and knockdown ESCs. Unfortunately, although *Lncenc1* can be re-expressed markedly, the expression of glycolysis and pluripotency genes still cannot be restored ([Figure S4](#mmc1){ref-type="supplementary-material"}). These data suggest that increased expression alone might not be sufficient for *Lncenc1* activity. Other factors might also contribute toward making *Lncenc1* functional, such as the location of expression in the genome, and the localization of the ectopic *Lncenc1* RNAs.

Next, we examined the glycolytic activity through functional assays. First we measured the glucose consumption and lactate production, the "in and out" of glycolysis, and found that they are both significantly decreased in *Lncenc1* knockdown ([Figure 5](#fig5){ref-type="fig"}A) and KO ([Figure 5](#fig5){ref-type="fig"}B) cells compared with the controls. We further examined glycolytic activity through glycolysis stress tests. As expected, the level of glycolytic activity was significantly decreased in knockdown cells as indicated by the measurement of the extracellular acidification rate (ECAR), which is largely the result of glycolysis ([Figure 5](#fig5){ref-type="fig"}C). We measured the initial pH in glucose-free culture medium (non-glycolysis). Then, to activate glycolysis, we sequentially added oligomycin (a mitochondrial ATP synthase inhibitor) to the culture medium. Both before and after activation, the glycolytic rate of control cells was significantly higher than that of knockdown cells ([Figure 5](#fig5){ref-type="fig"}D). It is notable that, when knockdown experiments were conducted with sh*Lncenc1*-1, which displayed better efficiency, glucose consumption, lactate production, and ECAR were all reduced by 50% or more. These data indicate that the glycolysis activity was severely impaired after the downregulation of *Lncenc1*.Figure 5Glycolic Activity Decreases upon *Lncenc1* Depletion(A and B) Measurements of glucose uptake and lactate production in *Lncenc1* knockdown (A) or KO (B) nESCs. Shown are results of three replicates (means ± SD). Statistical significance of t test: ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(C and D) Results of glycolysis stress tests as measured by the glucose-dependent extracellular acidification rate (ECAR). Shown are measurements of at least five replicates (means ± SD). Statistical significance of t test: ^∗∗∗^p \< 0.001.

*Lncenc1* Functionally Interacts with HNRNPK and PTBP1 {#sec2.5}
------------------------------------------------------

To identify potential partners of *Lncenc1*, we performed the RNA pull-down assay using biotin-labeled probes. Compared with the antisense control, the pull-down sample with sense probe showed two specific bands on the SDS-PAGE gel, which were identified as PTBP1 and HNRNPK by mass spectrometry and further validated by western blotting ([Figure 6](#fig6){ref-type="fig"}A). Moreover, results of RNA immunoprecipitation against PTBP1 and HNRNPK antibodies showed that *Lncenc1* RNAs are highly enriched compared with the other six lncRNAs tested ([Figure 6](#fig6){ref-type="fig"}B), which further confirmed interactions between *Lncenc1* and these two proteins. The yeast two-hybrid assay showed that PTBP1 and HNRNPK interact with each other ([@bib30]), and they interact as part of a complex in murine ESCs ([@bib35]). We then investigated whether PTBP1 and HNRNPK are functionally related to *Lncenc*1. As expected, knockdown of *Ptbp1* or *Hnrnpk* resulted in a significant downregulation of pluripotency and glycolysis genes ([Figures 6](#fig6){ref-type="fig"}C and 6D) and a significant reduction of glucose consumption and lactate production ([Figure 6](#fig6){ref-type="fig"}E), which is consistent with phenotypes observed in *the Lncenc1* knockdown or KO cells. These data indicated that *Lncenc1*, PTBP1, and HNRNPK are interacting physically and functionally.Figure 6*Lncenc1* Associates with HNRNPK and PTBP1 Functionally(A) Results of RNA pull-down experiments. Biotinylated *Lncenc1* sense or antisense RNAs were used for the experiments. Two specific bands (arrowheads) were excised and subjected to mass spectrometry analysis, and were further validated by western blotting.(B) RNA immunoprecipitation (RIP) with anti-HNRNPK and anti-PTBP1 antibodies in E14 nESCs. Enrichments of lncRNAs, i.e., expression of RIP relative to input samples, were determined by qRT-PCR.(C and D) Expression of pluripotency genes (C) or glycolysis genes (D) upon knockdown of *Ptbp1* and *Hnrnpk*. Data were normalized against *Actb*, and shown as the means ± SD of three independent experiments. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(E) Glycolysis signatures of Hnrnpk and Ptbp1 knockdown cells. Data were presented as means ± SD.(F--H) Chromatin immunoprecipitation (ChIP) experiments with HNRNPK (F) or RNA polymerase II (G) antibodies; CHIRP experiment with specific anti-*Lncenc1* probes (H). Relative enrichment of ChIP or CHIRP and input DNA were determined by qPCR. Primers were designed at promoters of glycolysis genes, pluripotency genes, and control genes (*B2m* and *Actb*), and two intergenic regions were used as negative controls. Data are shown as means ± SD of three independent experiments. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

To test whether the *Lncenc1*-PTBP1-HNRNPK complex regulates the expression of pluripotency and/or glycolysis genes, we performed chromatin immunoprecipitation (ChIP) experiments in *Lncenc1* knockdown and control nESCs. Indeed, HNRNPK binds to the promoters of pluripotency and glycolysis genes. However, only the occupancy of HNRNPK on glycolytic genes, but not pluripotency genes, were significantly decreased in knockdown cells compared with the control cells ([Figure 6](#fig6){ref-type="fig"}F). Furthermore, the occupancy of RNA polymerase II on glycolysis gene promoters decreased significantly upon *Lncenc1* or PTBP1 knockdown ([Figures 6](#fig6){ref-type="fig"}G and [S5](#mmc1){ref-type="supplementary-material"}). In addition, we performed chromatin isolation by RNA purification (ChIRP) assay in *Lncenc1* knockout and control nESCs. Consistent with our ChIP data, *Lncenc1* occupied the promoters at four of the five glycolytic genes ([Figure 6](#fig6){ref-type="fig"}H). These data suggested that *Lncenc1* guides HNRNPK and PTBP1 binding to glycolysis genes; therefore promoting their levels of transcription.

Interplays among *Lncenc1*, Core Pluripotency Networks, and Glycolytic Genes {#sec2.6}
----------------------------------------------------------------------------

Given that *Lncenc1* can affect self-renewal and glycolysis, we were curious about the regulatory relationships among them. First, upon the knockdown of the individual pluripotency gene (*Oct4*, *Sox2*, *Nanog*, or *Klf4*) ([Figure S6](#mmc1){ref-type="supplementary-material"}A), *Lncenc1* and all examined glycolysis genes were downregulated consistently ([Figure 7](#fig7){ref-type="fig"}A). Second, a recent study showed that core pluripotency factors directly regulate expression of glycolysis genes ([@bib29]), and that the *Lncenc1* locus is enriched for the binding of OCT4 ([Figure 1](#fig1){ref-type="fig"}C), indicating that *Lncenc1* and glycolysis genes are regulated directly by core pluripotency factors.Figure 7Regulatory Relationships among *Lncenc1*, Pluripotency Genes, and Glycolysis Genes(A--C) Expression of *Lncenc1* and glycolysis genes when individual pluripotency genes were knocked down (A); expression of *Lncenc1* and pluripotency genes when individual glycolysis genes were knocked down (B); and expression of *Lncenc1* and pluripotency genes upon knockdown of all five glycolysis genes (GGs) (C). For qRT-PCR experiments, expression levels were normalized against *Actb*, and data are shown as means ± SD of three independent experiments. Statistical significance of t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(D) Working model of *Lncenc1* in nESCs.

In contrast, knockdown of individual glycolysis genes failed to downregulate *Lncenc1* and pluripotency genes, except for *Klf4* ([Figures 7](#fig7){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}B). However, when all these five glycolysis genes were knocked down together (with two sets of shRNA pools), *Lncenc1* and pluripotency genes were all markedly declined ([Figures 7](#fig7){ref-type="fig"}C, [S6](#mmc1){ref-type="supplementary-material"}C, and S6D). Furthermore, the adding of 2-deoxy-D-glucose (2-DG) (a glycolysis inhibitor) to the 2i/LIF medium leads to "flatter" clone morphology and significant decreases of pluripotency gene expression ([Figure S6](#mmc1){ref-type="supplementary-material"}E). These data suggested that the glycolysis pathway, rather than individual genes, regulates the core pluripotency genes.

In summary, our data suggested that *Lncenc1*, PTBP1, and HNRNPK form functional complexes, which promote expression of glycolysis genes, thereby maintaining the glycolytic activity, which is required for the self-renewal of naive ESCs ([Figure 7](#fig7){ref-type="fig"}D).

Discussion {#sec3}
==========

Functional studies indicated that some lncRNAs regulate self-renewal or pluripotency through integrating or disturbing core pluripotency networks. For example, *Gomafu* regulates *Oct4* and *Nanog* expression through the formation of a positive feedback loop with *Oct4* ([@bib49]), and *TUNA* maintains self-renewal of mESCs through promoting transcriptional activities of pluripotent genes including *Nanog*, *Sox2*, and *Fgf4* ([@bib27]). However, an *Oct4* pseudogene lncRNA guides SUV39H1, a repressive chromatin modifier, to the promoter and epigenetically silences the *Oct4* gene in differentiated cells ([@bib48]). Similarly, in somatic cells, lincRNA-p21 interacts with SETDB1, which silences pluripotency genes by depositing histone H3K9me3 on their promoters ([@bib2]). Furthermore, linc-ROR promotes reprogramming by repressing pathways including P53 responses ([@bib37]), and this lncRNA maintains self-renewal of human ESCs through sponging miR-145, which targets mRNAs of core pluripotency genes ([@bib57]). Recently, Austin Smith and colleagues reported that the lncRNA *Ephemeron* modulates the exit from naive pluripotency by connecting microRNA and *de novo* DNA methylation ([@bib3]). In this study, we demonstrate that *Lncenc1* maintains self-renewal by regulating the glycolysis pathway. To our knowledge, *Lncenc1* is the first lncRNA linking self-renewal and energy metabolism in PSCs.

We showed that *Lncenc1* interacts with two RNA binding proteins (RBPs), PTBP1 and HNRNPK. Interestingly, the lncRNA *TUNA* also interacts with PTBP1 and HNRNPK, activating pluripotency genes directly ([@bib27]). However, *linc-p21* interacts with HNRNPK and SETBD1, silencing rather than activating its target genes in somatic cells ([@bib2]). PTBP1 is required for embryonic development ([@bib51]), and HNRNPK could interact with multiple proteins through its K interactive region to play various roles in diverse cellular processes ([@bib16]). Based on these data, we propose that a class of RBPs such as HNRNPK could form complexes with different lncRNAs and/or proteins that regulate specific classes of genes in different cell types. Further investigations are needed to reveal the functions of lncRNA-RBP complexes in various biological systems.

Recently, energy metabolism has been closely linked to stem cell fates. For example, during the ESC-to-EpiSC transition, energy metabolism switched from bivalent (utilization of both glycolysis and oxidative phosphorylation) to exclusively glycolytic, and hypoxia inducible factor 1a was sufficient to drive ESC to an EpiSC-like stage ([@bib58]). A recent metabolome analysis further indicated that, although early metabolites are increased, downstream glycolysis metabolites are decreased in primed hESCs ([@bib50]). Interestingly, when mESCs adapted from serum to 2i conditions, the glycolysis pathway was significantly upregulated as detected by RNA-seq ([@bib40]). Similarly, protein levels of glycolysis enzymes are significantly increased in naive ESCs compared with ESCs cultured in serum ([@bib53]). Our data further demonstrate that the downregulation of glycolysis by *lncenc1* depletion impairs self-renewal, which suggests that a high level of glycolysis is vital for naive ESCs. However, it remains unclear how glycolysis regulates naive pluripotency. It is possible that a faster generation of ATPs by glycolysis benefits highly proliferative cells including stem cells and cancer cells, or that glycolysis-generated metabolites are essential for establishing the epigenetic modifications required for the maintenance of PSCs ([@bib34], [@bib43], [@bib50]). Further investigations are required to decipher the detailed mechanisms underlying glycolysis and naive pluripotency states. Moreover, it would be possible to optimize culture systems for PSCs by manipulating metabolic status by adding or removing specific glycolysis metabolites.

Nevertheless, it remains elusive how *Lncenc1* functions *in vivo*, and developing *Lncenc1*-deficient mouse models will be critical in addressing this question. *Lncenc1* RNAs locate both in nucleus and cytoplasm. In this study, we investigated the functions of the nuclear *Lncenc1*, yet the activity of cytoplasmic *Lncenc1* remains to be explored in the future. Finally, as exemplified by *Lncenc1* and other lncRNAs regulating glycolysis in cancer ([@bib2], [@bib12], [@bib16], [@bib46]), it would be interesting to explore further functional roles of different lncRNAs in regulating energy metabolism in stem cells, development, and diseases.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

To maintain ESCs in ground state or naive state, cells from two mouse ESC lines (E14TG2a and R1) were cultured in 2i /LIF conditions as described ([@bib33]). The nESC-to-EpiLC transition was conducted as described ([@bib21]) with minor modifications. For spontaneous differentiation, nESC cells were plated at a density of 1 × 10^4^ per cm^2^ in gelatin-coated plates in N2B27 medium without 2i/LIF for 4 days. For the 2-DG treatment, nESCs were cultured in 2i/LIF medium for 1 day and then treated with 2-DG (100 mM) for 2 days.

RNA-Seq and Data Analysis {#sec4.2}
-------------------------

Total RNA was prepared with TRIzol reagents (Life Technologies). For RNA-seq experiments, rRNA-depleted and strand-specific libraries were constructed with the Ribo-zero gold (Epicentre) and TruSeq Stranded Total RNA Sample Prep Kit (Illumina), and the libraries were sequenced using the HighSeq 2000 system (Illumina). The analyses of RNA-seq data, including raw data processing, mapping, and gene expression, were conducted as described previously ([@bib14]). For differential gene expression analysis, we analyzed raw read counts for GENCODE M7 gene models using the HTSeq software ([@bib1]), and then calculated statistics of DE via DESeq2 ([@bib38]) with default parameters. To define differentially expressed genes, we used a false discovery rate of 0.05 (ESC-EpiLC comparison) or 0.1 (*Lncenc1* knockdown studies) as thresholds. We performed KEGG pathway analysis using DAVID bioinformatics tools as described ([@bib22]).

Northern Blot Analysis {#sec4.3}
----------------------

For northern blotting, 10 μg of total RNAs was mixed with 2× loading buffer (Fermentas), incubated at 55°C for 5 min, and resolved by denaturing agarose gel electrophoresis; the RNAs were then transferred to a nylon membrane and crosslinked by UV irradiation. Digoxigenin-labeled RNA probe preparation, hybridization, and detection were conducted via a DIG Northern Starter Kit (Roche) according to the manufacturer\'s protocol.

Cellular Fractionation {#sec4.4}
----------------------

Cellular fractionation experiments were performed with 1 × 10^7^ nESCs as described previously ([@bib5]).

Gene Knockdown {#sec4.5}
--------------

The shRNA-based knockdown experiments were conducted as described previously ([@bib2]). The validated shRNA sequences were provided in [Table S3](#mmc1){ref-type="supplementary-material"}. For ASO-mediated knockdown, we used phosphorothioate-modified oligodeoxynucleotides ([@bib23]). Two independent ASOs targeting *Lncenc1* (mUmCmCmUmUAAGGTGCTTCmAmGmTmTmC, and mGmUmCmAmUGCTGATGCTGmGmUmGmCmA), and one control ASO (mCmCmUmUmCCCTGAAGGTTmCmCmUmCmC) were synthesized (BioSune). Then 2 × 10^5^ nESCs were transfected with 100 μM of each ASO with 6 μL RNAiMAX (Life Technologies) and harvested 48 hr after the transfection.

Gene Knockout {#sec4.6}
-------------

To deplete the *Lncenc1* locus in E14 ESCs, we applied CRISPR/Cas9-based assays as described ([@bib8]). Two pairs of guide RNAs (pair1: GAGCCAATCTCTAGGCAAGT and GTATGACAAATGCTTATTGA; pair2: GTGCTTTTGTGTTATCCCGG and GGTCCATTATGTAACCACCT) were used to target the *Lncenc1* genomic locus, deleting regions about 15 kb (pair1) and 3 kb (pair2), respectively. *Lncenc1* knockouts were verified by genomic DNA PCR and sequencing.

Overexpression {#sec4.7}
--------------

The *Lncenc1* cDNA was cloned into the pcDNA3.1 vector, and the overexpression experiments were performed with electroporation by the Neon system (Invitrogen), according to the manufacturer\'s instructions.

qRT-PCR {#sec4.8}
-------

The qRT-PCR experiments were conducted as described ([@bib2]). Primer sequences for qRT-PCR are listed in [Table S4](#mmc1){ref-type="supplementary-material"}.

Western Blotting {#sec4.9}
----------------

Total cell lysates were prepared in 1× SDS buffer. An equal amount of proteins were separated by SDS-PAGE gel electrophoresis and transferred onto polyvinylidene difluoride membranes. The following antibodies were used for western blotting: anti-HNRNPK (Abcam, ab39975), anti-PTBP1 (Invitrogen, 324800), anti-PFKP (Proteintech, 13,389), anti-ALDOC (Proteintech, 14,884), anti-TPI1 (Proteintech, 10,713), anti-LDHA (Proteintech, 14,824), anti-PGK1 (Proteintech, 17,811), anti-SOX2 (Proteintech, 11,064), anti-H3 (Abcam, ab1791), anti-ACTB (Proteintech, 60,008-1-Ig), OCT4 (Santa Cruz, sc-8628). The blots were developed with ECL Plus Western Blotting Substrate (Thermo Scientific), and imaged by the FluorChem M System (ProteinSimple).

RNA Fluorescence *In Situ* Hybridization {#sec4.10}
----------------------------------------

RNA fluorescence *in situ* hybridization for the detection of *Lncenc1* and *Ppib* (positive control) was performed using an RNAscope (Advanced Cell Diagnostics, Hayward, CA, 323100), according to the protocol provided by the manufacturer.

Alkaline Phosphatase Detection {#sec4.11}
------------------------------

ESCs were fixed with 4% paraformaldehyde and stained with the Alkaline Phosphatase Staining Kit (Millipore) according to the manufacturer\'s protocol.

Colony Formation {#sec4.12}
----------------

ESCs were plated at a density of 100 per cm^2^ in laminin-coated 6-well plates in 2i/LIF. The medium was changed every 3 days. After 6 days, colonies were fixed and stained for alkaline phosphatase. Colonies were counted using the ImageJ software.

The Measurement of Glucose Uptake and Lactate Production {#sec4.13}
--------------------------------------------------------

The same amount (1 × 10^6^) of control and knockdown or knockout ESCs were seeded on a well of 12-well plates in 0.5 mL of N2B27 medium containing 2i/LIF. After 6 hr, the culture medium was collected for glucose and lactate measurement, using the Cobas C311 Chemistry Analyzer (Roche), according to the manufacturer\'s instructions. The intracellular glucose consumption and lactate production were calculated by the concentration differences between cultured medium and the blank medium.

Seahorse XF Bioenergetic Analysis {#sec4.14}
---------------------------------

SeaHorse plates were pre-treated by coating with 0.1% gelatin. ECAR in mESCs were measured using the Seahorse XF96 bioanalyzer according to the manufacturer\'s protocols. Cells were seeded in an XF96 microplate at a density of 20,000 cells per well. Culture medium was changed to unbuffered XF assay medium at pH 7.4 (Seahorse Biosciences), supplemented with 5.5 mM glucose (Sigma) and 1 mM pyruvate for assay of glycolysis rates. Before assay, the microplate was transferred into a non-CO2 incubator at 37°C for 60 min. For the glycolysis stress test, after collecting baseline acidification rate data, cells were sequentially treated with 10 mM glucose, 1 mM oligomycin, and 50 mM 2-DG, and the subsequent changes were quantified. All metabolic profiles were normalized to cell numbers.

RNA Pull-Down Assay {#sec4.15}
-------------------

RNA pull-down experiments were performed as described previously ([@bib56]). Specific gel bands were excised and subject to mass spectrometry analysis.

RNA Immunoprecipitation {#sec4.16}
-----------------------

Mouse nESCs (1 × 10^7^) were subjected to nuclei isolation as described ([@bib11]). Nuclei were then resuspended in 1 mL of cold RNA immunoprecipitation (RIP) buffer (150 mM KCl, 25 mM Tris \[pH 7.4\], 5 mM EDTA, 0.5 mM DTT, 0.5% NP40, 100 U/mL RNAase inhibitor, 1× Complete) and sheared by sonication. For immunoprecipitation (IP), 2 μg of specific antibody (HNRNPK \[Abcam, ab39975\]; PTBP1 \[Invitrogen, 324800\]) or the control IgG (Cell Signaling Technologies, 2,729) was incubated with 6--10 mg supernatant at 4°C for 2 hr, then 20 μL of protein G magnetic beads (Invitrogen) were added to each IP sample and incubated at 4°C for 1 hr. The beads were collected and washed three times with RIP buffer. RNAs were extracted with TRIzol, and enrichment for each gene was determined by qRT-PCR.

ChIP {#sec4.17}
----

ChIP experiments were performed with 1 × 10^7^ mESCs as described previously ([@bib24]). The following antibodies were used for ChIP: anti-HNRNPK (Abcam, ab39975) and anti-RNA PolII (Abcam, ab817). Primers for ChIP-PCR were provided in [Table S5](#mmc1){ref-type="supplementary-material"}.

ChIRP {#sec4.18}
-----

ChIRP experiments were performed as described previously ([@bib7]). Probe sequences are provided in [Table S6](#mmc1){ref-type="supplementary-material"}.
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